In vitro Alzheimer’s Disease Models
– With human-relevant data
Supporting drug discovery, target validation, and preclinical studies
Bioneer has over 100 publications in CNS research, including collaborations with Lundbeck and Johnson & Johnson.
We offer human iPSC-based Alzheimer’s disease models designed to accelerate drug discovery, target validation, and preclinical development by generating human-relevant, translatable data.
Our models can help you study key disease mechanisms, such as amyloid-beta accumulation, and neuroinflammation linked to Alzheimer’s biology in a controlled in vitro setting.
Using cortical neurons and microglia, including optional gene-edited lines, we can represent both patient-specific and engineered disease variants.
The models can be configured as single-cell cultures or multi-cellular co-cultures, enabling functional readouts such as imaging-based analyses, inflammatory marker profiling, and phagocytotic turnover.
Together, this approach provides a robust platform to support confident decision-making in Alzheimer’s disease research and preclinical development.
Alzheimer’s disease affects more than 55 million people worldwide
… and this number is growing. Yet drug development in this field remains highly challenging. Complex disease biology and the lack of human-relevant animal models continue to limit pre-clinical to clinical translatability, which results in long development timelines, high costs and ultimately low success rates.
With less than 1 out of 25 Alzheimer´s drug development candidates reaching patients this disease area has one of the lowest drug development success rates in the industry.
There is a need for continued development of advanced human-relevant in vitro systems that address these challenges.
How we make Alzheimer’s disease research easier for you
Human-relevant neurons and glia
We provide human iPSC-derived cortical neurons, microglia, or both, allowing you to focus on the cell types most relevant to your Alzheimer’s disease study. Models can be adapted to different genetic backgrounds and implemented as single-cell systems or customizable neuron–glia co-cultures to capture physiologically relevant interactions.
Flexible study design
We tailor assays to meet the needs of your study, whether that involves early compound screening, dose-response testing, or detailed mechanistic evaluations.
Functional readouts
We can provide co-culture setups with functional endpoints such as imaging-based analyses, inflammatory marker profiling, and phagocytotic turnover.
Applications for our In vitro Alzheimer’s Disease Models
Drug discovery and compound evaluation
Screen and prioritize compounds using human-relevant models, addressing mechanisms linked to abeta aggregation, tau pathology, and neuroinflammation.
Target validation
Explore how targets are linked to Alzheimer’s disease biology using neuronal and glial models, including gene-edited lines, to gain mechanistic insight.
Preclinical support
Generate quantitative, human-relevant in vitro data to guide preclinical development and decision-making.
Supporting your Alzheimer’s research from cell to data
We offer end-to-end solutions, from patient-derived cell reprogramming and gene editing to advanced co-culture assays and functional analyses. Our team ensures every step, from cell preparation to data interpretation, is precise and reproducible, providing meaningful insights into Alzheimer’s pathology.
Explore our capabilities:
- Alpha-synuclein aggregation assay
- Seahorse Assays
- Multi Electrode Array (MEA) assays
- Hight Content Cell Imaging
- Gene Editing
- iPSC-derived Neurons
- iPSC-derived Astrocytes
- iPSC-derived Microglia
Working with us
Partnering with us means working with a dedicated project manager and a team of experienced scientists who stay closely engaged throughout your project. We combine flexible workflows with a collaborative, human-centered approach to ensure your research moves forward efficiently and with clarity.
Established expertise
Bioneer has supported the life science community since 1982, building a strong foundation in science and technology and a solid track record in CNS research and disease modelling.
A human-centered way of working
We value close collaboration and long-term relationships, focusing on clear communication and trust at every stage of a project.
Our CNS leadership
Bjørn Holst,
Dept. Head of Cellular Engineering and Disease Models
Kenneth Thirstrup,
R&D Manager, CNS Assays
FAQ – about our in vitro Alzheimer’s Disease Models
Practical Questions
Can I talk to someone about my project before getting started?
Absolutely. By filling out the contact form on this page, we can set up a no-obligation conversation to discuss your project and your needs. We’re always happy to explore ideas with you and help identify the best way forward.
How does a project typically move forward?
We usually start with an initial conversation to understand your research goals and what you want to achieve.
From there, we work with you to design the study, including the most relevant Alzheimer’s disease models, assays, and a realistic timeline.
Throughout the project, we stay in close contact, provide regular updates, and remain flexible if your needs change.
At the end of the study, we deliver a clear overview of the results, including scientific interpretation and recommendations. And of course, we’re always available for follow-up questions or continued support.
Model and scientific relevance
How do your in vitro Alzheimer’s disease models reflect key disease mechanisms?
Our models focus on disease-relevant cell types and mechanisms involved in Alzheimer’s disease, including amyloid-beta–related processes, tau biology, and neuroinflammation. We work with human iPSC-derived cortical neurons and microglia to capture biologically relevant aspects of the disease in a human in vitro setting.
Can models be tailored to specific research questions or genetic backgrounds?
Yes. Depending on your study objectives, models can be adapted to different genetic backgrounds relevant to Alzheimer’s disease and implemented as single-cell systems or neuron-glia co-cultures. This flexibility allows us to tailor studies to specific research questions and mechanistic interests.
What types of readouts are available in your Alzheimer’s disease models?
We offer a range of disease-relevant readouts, including inflammatory marker profiling, imaging-based analyses, and measurements of microglial phagocytotic activity. These readouts are designed to provide clear, translatable insights into Alzheimer’s disease–related mechanisms.
What are the main technologies used to characterize model functionality?
The methods are defined together with you based on your project needs and may include imaging or TR-FRET analysis of selected responsive markers, multiplex analysis of secreted analytes using Luminex, and electrophysiological readouts measured with multielectrode arrays.
Can assays be adapted for screening as well as mechanistic studies?
Yes. Assays can be configured for different study formats, including compound screening, dose-response studies, and more detailed mechanistic investigations, depending on the needs of your project.
Contact us for a free consultation
Interested in learning how we can support your project or pipeline?
We´re always happy to chat.
For further information please contact Business Development Manager Jacob Mathias Bech on jmb@bioneer.dk or +4523202576
For further information please contact Business Development Manager Jacob Mathias Bech on jmb@bioneer.dk or +4523202576
